UBS raised the firm’s price target on Encompass Health (EHC) to $140 from $130 and keeps a Buy rating on the shares. Fundamentals remained strong in Q2, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Reports Strong Q2 2025 Results
- Encompass Health Reports Strong Q2 Earnings Growth
- Closing Bell Movers: Palantir hits record highs on beat and raise
- Encompass Health: Strong Financial Performance and Positive Outlook Justify Buy Rating Despite Stock Volatility
- Encompass Health Reports Strong Q2 2025 Financial Results